雙食慾素受體拮抗劑市場報告：至2031年的趨勢、預測與競爭分析

全球雙食慾素受體拮抗劑市場前景光明，醫院和診所市場以及零售藥局市場都蘊藏著巨大的機會。預計2025年至2031年期間，全球雙食慾素受體拮抗劑市場的年複合成長率將達到7.8%。這個市場的主要促進因素包括失眠症盛行率的上升、對更優治療方案的需求不斷成長，以及人們對睡眠障礙的認知不斷提高。

• Lucintel 預測，根據類型，daridorexant預計在預測期內實現最高成長。
• 從應用來看，醫院和診所預計將經歷高速成長。
• 根據地區，預計北美將在預測期內實現最高成長。

雙食慾素受體拮抗劑市場的新趨勢

雙食慾素受體拮抗劑市場正見證一系列新興趨勢，這得益於藥理學的進步、睡眠障礙盛行率的上升以及消費者偏好的變化。隨著對食慾素受體認知的不斷加深，研究新的適應症和劑型，以滿足各種患者的需求。這些趨勢引領DORA市場的未來，並創造成長機會。

• 個人化睡眠療法：DORA 的一個發展方向是邁向個人化睡眠療法。隨著研究的進步，藥物正日益個人化，以滿足患者的需求，並考慮到患者的基因組成、睡眠行為以及對各種疾病的易感性。這一趨勢使得更有效、更個人化的治療能夠解決睡眠障礙的根本原因，使基於 DORA 的藥物更加有效和安全。因此，個人化療法將成為 DORA 市場的重要組成部分，為患者提供量身定做的解決方案。
• 非成癮性治療：對非成癮性睡眠藥物日益成長的需求推動了 DORA 市場的發展。與鎮靜劑和苯二氮平類催眠藥不同，DORA 不會產生依賴性或戒斷症狀的風險。這使得 DORA 對尋求長期治療睡眠障礙且無成癮風險的患者越來越有吸引力。隨著人們對使用傳統睡眠藥物相關風險的認知不斷提高，對 DORA 的需求可能會成長，尤其是在那些對藥物依賴性擔憂較高的國家。
• 睡眠障礙的聯合治療：人們越來越關注將雙食慾素受體拮抗劑與其他藥物類別聯合使用，以治療失眠和發作性睡病等複雜的睡眠障礙。將雙食慾素受體拮抗劑（DORA）與抗憂鬱症和抗精神病藥物等其他藥物合併使用，可望提高整體治療效果，並同時治療多種潛在疾病。這一趨勢有望為 DORA 市場帶來新的治療機會，為患有更嚴重健康問題的患者提供完整的解決方案。
• DORA 對其他疾病的研究：儘管 DORA 主要用於治療睡眠障礙，但目前也存在著探索其在其他神經系統疾病中的治療潛力的趨勢。目前進行研究，以探索如何利用 DORA 治療焦慮症、憂鬱症，甚至阿茲海默症疾病。 DORA 能夠調節與覺醒和喚醒有關的食慾素受體，使其成為更廣泛治療的良好候選藥物。這一趨勢可能為 DORA 創造更大的市場，並使其成為神經系統領域的多功能藥物。
• 更多監管核准和臨床試驗：隨著DORA不斷證明其在治療睡眠障礙方面的有效性，越來越多的臨床試驗進行，監管機構也核准更多 DORA 藥物。隨著人們對改善睡眠品質和應對全球睡眠障礙發病率快速上升的興趣日益濃厚，越來越多的製藥公司投資基於 DORA 的療法。隨著新產品的湧現和臨床資料的積累，這一趨勢將增加治療選擇，並推動市場進一步成長。

雙食慾素受體拮抗劑市場的新趨勢，例如對個人化睡眠治療、非成癮性治療和聯合療法的研究，顯著改變行業格局。這些趨勢預示著睡眠障礙治療將持續朝著更有效率、更安全的個人化方向發展，為未來幾年 DORA 市場的成長和創新奠定了基礎。

雙食慾素受體拮抗劑市場的最新趨勢

近年來，雙食慾素受體拮抗劑市場取得了顯著進展，這得益於睡眠障礙研究活動的活性化、監管部門的核准以及製劑的改進。所有這些進展都提高了基於雙食慾素受體拮抗劑（DORA）療法的療效，並為患有睡眠障礙和其他繼發性併發症的患者提供了新的治療途徑。以下是重塑市場的五個最重要的新興市場發展：

• FDA核准Suvorexant：2014年，美國FDA核准Suvorexant（Balsara）是 DORA 市場的一個重要里程碑。作為該類別的首個治療藥物，Balsara 現已成為失眠症患者最廣泛的治療選擇之一。這項核准為 DORA 的進一步開發鋪平了道路，進一步凸顯了食慾素受體拮抗劑在誘導睡眠方面的功效。 Balsara 的成功促使人們進一步研究其他有前景的DORA 藥物，增加了失眠和睡眠障礙的治療方法。
• 研發的DORA藥物：許多製藥公司開發新型雙食慾素受體拮抗劑，以滿足日益成長的睡眠藥物需求。這些藥物進行臨床試驗，以驗證其在治療失眠、發作性睡病和其他睡眠相關疾病方面的安全性和有效性。隨著目的是提高DORA療效並減少其副作用的研究不斷進行，這些新藥預計將對市場產生重大影響，並為患者提供更多治療選擇。
• DORA 全球可近性不斷擴大：隨著越來越多的國家核准DORA，DORA 的全球市場日益擴大。 Suvorexant 已在多個國家獲批，隨著臨床資料的積累，更多基於 DORA 的藥物有望獲得批准。該成長將有助於滿足全球對安全有效的睡眠藥物日益成長的需求。預計 DORA 藥物的可近性將增強市場競爭力，並改善全球消費者的治療效果。
• 重視非成癮性療法：隨著人們對傳統鎮靜劑危害的擔憂日益加深，人們越來越重視開發非成癮性助眠劑。 DORA 在這方面處於領先地位，因為它們不會像其他睡眠藥物那樣帶來成癮風險。隨著患者和醫療保健專業人員都在尋求更安全、更長期的失眠和其他睡眠障礙治療方法，對基於 DORA 的治療方法的需求也日益成長。
• 拓展 DORA 適應症的研究：除睡眠障礙外，DORA 的適應症研究加速進行。其作為焦慮症和憂鬱症神經精神疾病以及阿茲海默症神經退化性疾病的治療潛力被探索。如果這些研究取得成功，DORA 的治療領域將大幅擴展，為多種疾病的治療開闢新的典範。應用範圍的拓展有望成為市場擴張和技術創新的驅動力。

雙食慾素受體拮抗劑市場的重大進展，包括監管部門的核准、開發新藥以及全球藥局的擴大，必將推動睡眠障礙治療領域的進一步發展和創新。隨著更多藥物上市以及更多適應症的研究，DORA 市場將大幅擴張，並惠及病患和製藥公司。

目錄

第1章 執行摘要

第2章 全球雙食慾素受體拮抗劑市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章 2019年至2031年市場趨勢及預測分析

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球雙食慾素受體拮抗劑市場趨勢（2019-2024）及預測（2025-2031）
• 依類型
  • Suvorexant
  • Lemborexant
  • Daridorexant
• 依用途
  • 醫院和診所
  • 零售藥局
  • 其他

第4章 2019年至2031年區域市場趨勢與預測分析

• 依地區
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第5章 競爭分析

• 產品系列分析
• 運作整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 依類型
  • 依用途
  • 依地區
• 全球雙食慾素受體拮抗劑市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球雙食慾素受體拮抗劑市場產能擴張
  • 全球雙食慾素受體拮抗劑市場的合併、收購與合資企業
  • 認證和許可

第7章 主要企業簡介

• Merck
• Eisal
• Idorsia
• Takeda

The future of the global dual orexin receptor antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global dual orexin receptor antagonist market is expected to grow with a CAGR of 7.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of insomnia, the increasing demand for better treatments, and the growing awareness of sleep disorders.

• Lucintel forecasts that, within the type category, daridorexant is expected to witness the highest growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market is seeing a number of emerging trends, fueled by advancements in pharmacology, the rising incidence of sleep disorders, and changing consumer preferences. As knowledge about orexin receptors grows, new indications and drug formulations are being investigated to address various patient needs. These trends are guiding the future of the DORA market and creating opportunities for increased growth.

• Customized Sleep Therapies: A trend in DORA's direction is seen to move toward customized sleep therapies. With growing advancements in research, more medicines are being made personalized to fit patients' requirements specifically, considering their genetic structure, sleep behaviors, and predisposition to various medical conditions. This trend is making it possible to have more efficient and personalized treatments that address the underlying causes of sleep disorders, making DORA-based medicines more effective and safer. Consequently, personalized therapies will be a major component of the DORA market, providing patient-specific solutions.
• Non-Habit-Forming Treatments: Rising demand for non-habit-forming sleep medications is creating a drive in the DORA market. Unlike sedatives and benzodiazepines, DORAs have no risk of dependence or withdrawal symptoms associated with them. This has rendered DORAs increasingly appealing to patients who desire long-term remedies for sleep disorders without the risk of addiction. As people become more aware of the risks associated with the use of conventional sleep medicines, demand for DORAs will increase, particularly in countries where there is high concern about dependency on medications.
• Combination Therapies for Sleep Disorders: There is increasing interest in combining dual orexin receptor antagonists with other drug classes to treat complicated sleep disorders, such as insomnia and narcolepsy. By combining DORAs with other therapeutic drugs, such as antidepressants or antipsychotics, scientists are hoping to enhance the overall effectiveness of treatments and treat multiple underlying conditions at once. This trend will lead to new opportunities for therapy in the DORA market and give patients with more severe health problems complete solutions.
• DORA Research for Other Disorders: Even though DORAs are utilized mostly for sleep disorders, a trend is observed towards exploring their therapeutic potential in other neurological diseases. Studies are in progress to discover how to use DORAs in the treatment of diseases such as anxiety, depression, and even Alzheimer's. Since DORAs can modulate orexin receptors, which are involved in wakefulness and arousal, they are a strong contender for a broader therapy. This trend could make the market for DORAs much larger and position them as multi-purpose drugs within the neurological arena.
• More Regulatory Approvals and Clinical Trials: As DORAs continue to show their efficacy in the treatment of sleep disorders, more clinical trials are being undertaken and regulatory agencies are approving more DORA drugs. The growing interest in bettering the quality of sleep and tackling the worldwide surge in sleep disorders is causing more pharmaceutical firms to invest in DORA-based therapy. This trend should result in an increase in treatment options, fueling further market growth as new products emerge and clinical data continue to accrue.

The new trends in the dual orexin receptor antagonist market, including personalized sleep treatments, non-addictive treatments, and studies on combination treatments, are greatly transforming the industry landscape. These trends are indicative of a continued move towards more efficient, safer, and personalized treatments for sleep disorders, setting the DORA market up for future growth and innovation over the next few years.

Recent Developments in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market witnessed significant progress in recent years, fueled by rising research activity in sleep disorders, approvals from the regulatory authorities, and advancements in formulations. All these advances have enhanced the efficacy of DORA-based treatments, presenting patients suffering from sleep disorders and other secondary complications with new avenues for treatment. Five of the most significant developments that are remaking the market are discussed below.

• FDA Approval of Suvorexant: The US FDA approval of Suvorexant (Balsara) in 2014 was a major benchmark for the DORA market. As the inaugural drug of this category, Balsara is now one of the largest treatment options available to patients of insomnia. This endorsement has opened the door to additional development of DORAs and has highlighted further the effectiveness of orexin receptor antagonism in inducing sleep. The success of Balsara has encouraged further research into other promising DORA drugs, increasing the treatments available for insomnia and sleep disorders.
• Pipeline DORA Drugs in Development: A number of pharmaceutical firms are developing novel Dual Orexin Receptor Antagonists to meet the increasing demand for sleep medicines. The drugs are being tested in clinical trials to determine their safety and effectiveness in the treatment of diseases such as insomnia, narcolepsy, and other sleep-related disorders. With constant research aimed at enhancing the efficacy of DORAs and reducing side effects, these new drugs have the promise to make a significant impact on the market and offer more treatment alternatives for patients.
• DORA Availability Widening Globally: With increased countries approving DORA drugs, the global market for these drugs is widening. Suvorexant has already been licensed in some countries, and more DORA-based medications are likely to be licensed as clinical data continue to accumulate. This growth is assisting in meeting increasing global demand for safe and effective sleep medications. Greater availability of DORA medications will be expected to enhance market competitiveness and make for improved treatment for consumers globally.
• Emphasis on Non-Habit-Forming Therapies: As concerns about the dangers of conventional sedatives continue to grow, efforts are focused on creating non-habit-forming sleep aids. DORAs, which pose no risk of dependence like other sleeping medications, lead the charge. Patients and healthcare professionals alike are increasingly looking for safer long-term cures for insomnia and other sleep disorders, and recognizing this, demand for DORA-based therapies is increasing.
• Expanded Indications Research for DORAs: Research on the application of DORAs for indications other than sleep disorders is picking up speed. Investigations are looking into the possibility of these drugs being used to treat neurological and psychiatric diseases like anxiety, depression, and neurodegenerative conditions like Alzheimer's. If successful, these studies can drastically expand the therapeutic horizon for DORAs and result in new paradigms for the treatment of several diseases. This broadened application would fuel market expansion and innovation.

The major advancements in the dual orexin receptor antagonist market, such as regulatory approval, new drug development, and expanded global access, are leading the way towards additional growth and innovation in treating sleep disorders. With more drugs coming to the market and further research into more indications, the DORA market is set for dramatic expansion, to the advantage of both patients and pharmaceutical firms.

Strategic Growth Opportunities in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market offers many strategic growth opportunities in key applications, fueled by a growing awareness of sleep disorders and a growing emphasis on neurological health. These opportunities range across a number of therapeutic areas, from sleep disorders to psychiatric and neurological disorders, and are likely to define the future of the market.

• Growth in Emerging Markets: Emerging markets in Asia, Latin America, and Africa provide ample growth opportunities for the DORA market. With growing awareness of sleep disorders and increasing disposable incomes, demand for effective sleep aids is on the rise. Companies can customize their products to suit the particular requirements of these markets, increasing their reach through localized marketing channels and distribution networks.
• Expansion in Sleep Disorder Treatment: With the increasing incidence of sleep disorders such as insomnia, narcolepsy, and sleep apnea across the world, the market for dual orexin receptor antagonists is likely to grow. By targeting the enhancement of availability and affordability of DORA drugs for the treatment of sleep disorders, pharmaceutical companies can capitalize on this expanding market, particularly as more people look for non-habit-forming, effective treatments.
• Targeting Mental Health Disorders: Investigations into the potential application of DORAs in treating mental health disorders, including depression and anxiety, are creating new opportunities for market expansion. With the increasing demand for treatments that target both sleep disorders and psychiatric disorders, DORAs may provide a two-pronged approach to patient treatment. This potential makes DORAs central drugs for the treatment of sleep and mental health disorders.
• Emphasis on Personalized Medicine: Personalized medicine is taking center stage in the healthcare sector, and the DORA market is no different. By creating customized treatments that take into consideration patient-specific factors, including genetic factors and lifestyle, firms are able to maximize the safety and effectiveness of DORA-based medicines. This trend will propel market growth as patients are increasingly looking for customized treatment solutions that meet their specific needs.
• Combination Therapies with Wider Market Opportunities: Combination therapies of DORAs and other drug types, like antidepressants or antipsychotics, have considerable growth opportunities. These therapies have the goal to treat multiple basic conditions, for example, sleep disorders, anxiety, and depression, within one treatment protocol. Through the presentation of comprehensive remedies, combination therapies of DORAs have a wider market scope and can create new therapeutic avenues for complex diseased patients.

Strategic opportunities for growth in the dual orexin receptor antagonist market, fueled by emerging markets, mental health uses, personalized medicine, and combination therapies, will dramatically reshape the market landscape. Companies that target these opportunities will be well-positioned to succeed in this dynamic and fast-growing market.

Dual Orexin Receptor Antagonist Market Driver and Challenges

The dual orexin receptor antagonist market is influenced by several drivers and challenges such as technological innovations, economic considerations, and regulatory aspects. While they drive the market growth, they also pose challenges that have to be tackled by manufacturers. Through knowledge of these major drivers and challenges, companies can set themselves up for success.

The factors responsible for driving the dual orexin receptor antagonist market include:

1. Increasing Incidence of Sleep Disorders: With the global incidence of sleep disorders, including insomnia and narcolepsy, on the rise, there is a growing need for effective treatments such as dual orexin receptor antagonists. DORAs offer a novel and non-habit-forming alternative to conventional sedatives, fueling market growth.

2. Drug Formulation Innovations: Advances in drug technology are making it possible to develop more potent and targeted DORA-based medications. Innovative formulations that enhance the safety and effectiveness of the drugs are drawing in customers and healthcare professionals, driving the market further.

3. Increased Emphasis on Mental Health: The increased emphasis on mental health and its relationship with sleep disorders is fueling demand for DORA therapies. Addressing both sleep and psychological ailments, DORAs are now being recognized as a feasible treatment option, which is broadening their market scope.

4. Increasing Healthcare Spending: Increasing healthcare spending worldwide is driving the growth of the DORA market, as patients are increasingly opting for medical treatment for their sleep disorders. With increasing disposable income, patients are becoming more inclined to spend money on sophisticated treatments that provide long-term results.

5. Enlarging Clinical Research: Continuous clinical research into the therapeutic potential of DORAs for other neurological and psychiatric disorders, as well as sleep disorders, is a major growth driver for the market. With new indications for DORAs arising, the market for these medications is likely to grow.

Challenges in the dual orexin receptor antagonist market are:

1. Regulatory Hurdles: The regulatory process for the approval of DORA drugs is time-consuming and complex, especially in countries with strict pharmaceutical regulations. Companies need to overcome these issues to market their drugs on time.

2. Emerging Markets' Price Sensitivity: With demand for DORAs growing, price sensitivity is an area of difficulty, particularly in the emerging markets. Firms need to juggle the accessibility of their product alongside ensuring the same high level of quality and efficacy.

3. Alternative Treatment Competition: The DORA market competes with alternative treatments for sleep disorders, including benzodiazepines, melatonin, and other sedatives. Companies need to differentiate DORA-based therapies from these alternatives to remain competitive.

The challenges and drivers affecting the dual orexin receptor antagonist market mirror the dynamic nature of the sector. Although increased awareness, formulation advancements, and rising healthcare investment are fueling growth, regulatory barriers and price sensitivity remain current challenges. By addressing these variables, companies can more effectively deal with the intricacies of the market and take advantage of emerging opportunities.

List of Dual Orexin Receptor Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dual orexin receptor antagonist companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dual orexin receptor antagonist companies profiled in this report include-

• Merck
• Eisal
• Idorsia
• Takeda

Dual Orexin Receptor Antagonist Market by Segment

The study includes a forecast for the global dual orexin receptor antagonist market by type, application, and region.

Dual Orexin Receptor Antagonist Market by Type [Value from 2019 to 2031]:

• Suvorexant
• Lemborexant
• Daridorexant

Dual Orexin Receptor Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Dual Orexin Receptor Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dual Orexin Receptor Antagonist Market

The market for dual orexin receptor antagonist (DORA) has been expanding very quickly as a result of increasing interest in sleep disorders like insomnia and other neurological conditions associated with it. This category of drugs, acting on the orexin receptors involved in wakefulness regulation, is gaining popularity across the world because of its efficiency in inducing sleep without side effects compared to conventional sedatives. Major developments in the DORA market have been noted in key pharma markets such as the United States, China, Germany, India, and Japan, where research, clinical trials, and product approvals remain to define the market scenario.

• United States: In the United States, the market for dual orexin receptor antagonist has experienced considerable growth, especially with the regulatory approval of products such as Suvorexant (Balsara), the first DORA to be approved by the FDA for the treatment of insomnia. An increased need for effective treatments, fueled by the rising incidence of sleep disorders, has driven further interest in DORAs. U.S. market is marked by swift uptake of novel sleep aids, with continuous research aimed at enhancing the safety and effectiveness of the drugs. The regulatory environment is favorable, offering a clear line for further DORA drugs to come into the market.
• China: China is experiencing swift growth in the market for DORA as awareness about sleep disorders rises and more attention is being focused on mental health. The Chinese government has been investing in healthcare infrastructure, and increasing numbers of people are looking for treatments for insomnia and associated conditions. Although DORAs are relatively new to the market, consumers are increasingly interested in innovative sleep aids. Clinical trials and research are ongoing, and the market is likely to grow as the demand for safe and effective treatment for sleep disorders grows nationwide.
• Germany: Germany's DORA market is expanding steadily, with growing awareness of sleep disorders such as insomnia and narcolepsy. With the healthcare system providing significant support for mental health conditions, Germany has emerged as a leading market for the uptake of new treatments. Regulatory approvals for DORAs like Suvorexant and other upcoming drugs have improved treatment options for patients. Germany is targeting the betterment of sleeping quality and encouragement of safer alternatives to conventional sedatives. Having robust pharmaceutical corporations in Germany enhances ongoing research and development in this sector.
• India: In India, the DORA market remains nascent with very limited presence of orexin receptor-targeted drugs for sleeping disorders. Nonetheless, with the rising prevalence of insomnia and increased awareness of mental illness, there is a growing demand for successful treatments. The market is dominated by the embracement of Western medicine, yet there is a desire for cheaper drugs. Regulatory authorities in India are considering the approval of DORAs, and the market is expected to expand as knowledge of the advantages of DORA-based therapies spreads among the healthcare community and consumers.
• Japan: Japan has experienced strong growth in the DORA market, especially with the rising incidence of sleep disorders due to lifestyle and aging populations. Japanese pharmaceutical firms are at the forefront of creating DORA-based treatments, including the approval of Suvorexant. The need for safe and non-habit-forming sleep aids is increasing, and DORAs are a very promising treatment option. Japan's strong healthcare system and regulatory environment facilitate the ongoing development of this market. The emphasis is on providing effective treatments that ensure healthy sleep without the threat of dependence.

Features of the Global Dual Orexin Receptor Antagonist Market

Market Size Estimates: Dual orexin receptor antagonist market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Dual orexin receptor antagonist market size by type, application, and region in terms of value ($B).

Regional Analysis: Dual orexin receptor antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the dual orexin receptor antagonist market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dual orexin receptor antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dual orexin receptor antagonist market by type (suvorexant, lemborexant, and daridorexant), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dual Orexin Receptor Antagonist Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Dual Orexin Receptor Antagonist Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Dual Orexin Receptor Antagonist Market by Type
  • 3.3.1: Suvorexant
  • 3.3.2: Lemborexant
  • 3.3.3: Daridorexant
• 3.4: Global Dual Orexin Receptor Antagonist Market by Application
  • 3.4.1: Hospital & Clinic
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Dual Orexin Receptor Antagonist Market by Region
• 4.2: North American Dual Orexin Receptor Antagonist Market
  • 4.2.1: North American Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.2.2: North American Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.3: European Dual Orexin Receptor Antagonist Market
  • 4.3.1: European Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.3.2: European Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.4: APAC Dual Orexin Receptor Antagonist Market
  • 4.4.1: APAC Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.4.2: APAC Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.5: ROW Dual Orexin Receptor Antagonist Market
  • 4.5.1: ROW Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.5.2: ROW Market by Application: Hospital & Clinic, Retail Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Type
  • 6.1.2: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Application
  • 6.1.3: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Region
• 6.2: Emerging Trends in the Global Dual Orexin Receptor Antagonist Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dual Orexin Receptor Antagonist Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dual Orexin Receptor Antagonist Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Eisal
• 7.3: Idorsia
• 7.4: Takeda